Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:10:37.119Z.
Calculation as of: 2026-10-06T16:10:37.119Z.
Quote observation: 2026-10-06T16:10:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 026981202cadb8e73b6cbd63f18abfa8ffa74fea80ac6bbb32512047e0825b9f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$2.42B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.39B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.38B
EV/EBIT Ratio
11.33x
TTM Avg
17.19x
3Y Avg
119.55x
5Y Avg
119.55x
Market Cap
$2.35B
EV/EBIT Ratio
13.04x
TTM Avg
116.99x
3Y Avg
116.99x
5Y Avg
116.99x
Market Cap
$2.30B
EV/EBIT Ratio
8.26x
TTM Avg
7.33x
3Y Avg
8.48x
5Y Avg
15.70x
Market Cap
$2.27B
EV/EBIT Ratio
24.74x
TTM Avg
17.43x
3Y Avg
12.93x
5Y Avg
8.03x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.41B | N/A | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.42B | N/A | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.39B | N/A | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.38B | 11.33x | 17.19x | 119.55x | 119.55x |
| Disc Medicine, Inc. (IRON)vs › | $2.44B | N/A | N/A | N/A | N/A |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.37B | N/A | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.35B | 13.04x | 116.99x | 116.99x | 116.99x |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.30B | 8.26x | 7.33x | 8.48x | 15.70x |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.27B | 24.74x | 17.43x | 12.93x | 8.03x |
| Privia Health Group, Inc. (PRVA)vs › | $2.58B | N/A | 94.82x | 129.24x | 129.46x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
